GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » Cyclically Adjusted PS Ratio

IntelliPharmaCeutics International (TSXV:IPCI) Cyclically Adjusted PS Ratio : 0.05 (As of May. 21, 2024)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International Cyclically Adjusted PS Ratio?

As of today (2024-05-21), IntelliPharmaCeutics International's current share price is C$0.08. IntelliPharmaCeutics International's Cyclically Adjusted Revenue per Share for the quarter that ended in Aug. 2023 was C$1.56. IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio for today is 0.05.

The historical rank and industry rank for IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio or its related term are showing as below:

TSXV:IPCI' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.03   Med: 1.81   Max: 26.65
Current: 0.05

During the past years, IntelliPharmaCeutics International's highest Cyclically Adjusted PS Ratio was 26.65. The lowest was 0.03. And the median was 1.81.

TSXV:IPCI's Cyclically Adjusted PS Ratio is ranked better than
98.03% of 507 companies
in the Biotechnology industry
Industry Median: 5.55 vs TSXV:IPCI: 0.05

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IntelliPharmaCeutics International's adjusted revenue per share data for the three months ended in Aug. 2023 was C$0.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$1.56 for the trailing ten years ended in Aug. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


IntelliPharmaCeutics International Cyclically Adjusted PS Ratio Historical Data

The historical data trend for IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cyclically Adjusted PS Ratio Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.11 0.10 - 0.06

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.06 0.05 0.05 0.06

Competitive Comparison of IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio falls into.



IntelliPharmaCeutics International Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.08/1.56
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International's Cyclically Adjusted Revenue per Share for the quarter that ended in Aug. 2023 is calculated as:

For example, IntelliPharmaCeutics International's adjusted Revenue per Share data for the three months ended in Aug. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=0.003/125.3885*125.3885
=0.003

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201311 0.754 97.182 0.973
201402 2.196 98.051 2.808
201405 0.693 99.394 0.874
201408 0.502 99.315 0.634
201411 0.746 99.078 0.944
201502 0.607 99.078 0.768
201505 0.655 100.263 0.819
201508 0.462 100.579 0.576
201511 0.460 100.421 0.574
201602 0.320 100.421 0.400
201605 0.291 101.765 0.359
201608 0.254 101.686 0.313
201611 0.262 101.607 0.323
201702 0.540 102.476 0.661
201705 0.896 103.108 1.090
201708 0.488 103.108 0.593
201711 0.418 103.740 0.505
201802 0.122 104.688 0.146
201805 0.018 105.399 0.021
201808 0.124 106.031 0.147
201811 0.073 105.478 0.087
201902 0.023 106.268 0.027
201905 0.078 107.927 0.091
201908 0.102 108.085 0.118
201911 0.014 107.769 0.016
202002 0.022 108.559 0.025
202005 0.023 107.532 0.027
202008 0.017 108.243 0.020
202011 0.017 108.796 0.020
202102 0.000 109.745 0.000
202105 0.004 111.404 0.005
202108 0.000 112.668 0.000
202111 0.000 113.932 0.000
202202 0.003 115.986 0.003
202205 0.000 120.016 0.000
202208 0.001 120.569 0.001
202211 0.001 121.675 0.001
202302 0.013 122.070 0.013
202305 0.020 124.045 0.020
202308 0.003 125.389 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IntelliPharmaCeutics International  (TSXV:IPCI) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


IntelliPharmaCeutics International Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines